Bridgeway Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Bridgeway Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-42,400	Closed	-$248K	–	1452
2019 Q1	$248K	Hold	42,400	–	–	﹤0.01%	1193
2018 Q4	$55K	Sell	42,400 -178,792	-81%	-$311K	﹤0.01%	1334
2018 Q3	$763K	Buy	221,192 +139,900	+172%	+$525K	0.01%	1009
2018 Q2	$370K	Sell	81,292 -88,708	-52%	-$353K	﹤0.01%	1211
2018 Q1	$561K	Buy	170,000 +55,000	+48%	+$195K	0.01%	1058
2017 Q4	$449K	Sell	115,000 -1,800	-2%	-$9.8K	﹤0.01%	1123
2017 Q3	$1.21M	Buy	116,800 +1,800	+2%	+$17.7K	0.01%	774
2017 Q2	$1.12M	Hold	115,000	–	–	0.01%	780
2017 Q1	$782K	Hold	115,000	–	–	0.01%	900
2016 Q4	$633K	Hold	115,000	–	–	0.01%	985
2016 Q3	$872K	Buy	+115,000	New	+$841K	0.01%	859

Bridgeway Capital Management's IMDZ Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 42,400 shares — an estimated $248K sold.

Bridgeway Capital Management first reported a position in IMDZ in Q3 2016 and held it in 11 quarters. The position peaked at $1.21M in Q3 2017. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.

Bridgeway Capital Management reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 42,400 Immune Design Corp. shares in Q2 2019, an estimated $248K.
Bridgeway Capital Management first reported a position in Immune Design Corp. in Q3 2016 and held it in 11 quarters.
Bridgeway Capital Management's Immune Design Corp. position peaked at $1.21M in Q3 2017.
0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.